Shares of ProMIS Neurosciences, Inc. (OTCMKTS:ARFXF – Get Rating) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $4.83 and last traded at $4.78, with a volume of 3250 shares. The stock had previously closed at $4.98.

ProMIS Neurosciences Stock Performance

The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -442.00 and a beta of 1.08. The firm has a fifty day simple moving average of $5.56 and a 200 day simple moving average of $5.57. The company has a debt-to-equity ratio of 1.08, a current ratio of 10.37 and a quick ratio of 10.37.

About ProMIS Neurosciences

(Get Rating)

ProMIS Neurosciences, Inc discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.

Recommended Stories

• Get a free copy of the StockNews.com research report on ProMIS Neurosciences (ARFXF)
• Is Kintara Therapeutics A Hidden Gem?
• Should You Warm up to Generac Stock for the Winter?
• 3 High-Yield Dividend Stocks to Hold for the Long Haul
• Cal-Maine Posts Record Quarter, Remain CALM Income Investors
• Tesla Stock: What the Bulls and the Bears Are Getting Wrong

Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.